ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

MTFB Motif Bio Plc

0.50
0.00 (0.00%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Motif Bio Plc LSE:MTFB London Ordinary Share GB00BVVT4H71 ORD 0.01P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.50 0.40 0.55 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Motif Bio Share Discussion Threads

Showing 2626 to 2648 of 9925 messages
Chat Pages: Latest  109  108  107  106  105  104  103  102  101  100  99  98  Older
DateSubjectAuthorDiscuss
16/1/2019
17:24
Down 6%, top up ?
mike1608
16/1/2019
12:55
a week old but may be of interest to anyone who missed it...



FDA decision on Iclaprim expected February 13?

bountyhunter
16/1/2019
08:20
Looks like it tried to backtest 36p but support kicked in well before that level - missed the action yesterday but may get a chance to buy a dip today
return_of_the_apeman
15/1/2019
17:58
No delay here as pointed out clearly yesterday. Good day today, nice shake out ditching plenty traders/chancers followed by a good recovery back over 40p to finish with a touch of red to cool techs.

20 trading days left to Fda D day. Exciting times ahead.

ianb5004
15/1/2019
15:21
positive write up on sh-areprophets
andrbea
15/1/2019
13:51
This will probably end up blue today.
timberwolf3
15/1/2019
13:06
No just the ATs kicking in.
l4z4rus
15/1/2019
12:53
I assume the fall is now something to do with FDA shutdown. Everything's getting delayed.
waterloo01
15/1/2019
12:27
Buy for the medium-long term imo nai dyor
bountyhunter
15/1/2019
12:16
Hold or sell?
mike1608
15/1/2019
10:19
This one had a phenomenal run from 25 to 40p, a 60% rise. I expect a correction now to the mid 30s. Also, during the new year many would have bought this for extended settlements which would now be due for settlement. This could cause further pressure on the share price.
infoanish
15/1/2019
07:37
Sorry - I mean FDA running out of cash! Seems around March...
123js
15/1/2019
07:30
123JS

AS long as they don't try to fund any novel developments themselves cash should be ample - hence the likelihood is going to be a partnership - announced very soon the proce action suggests. Where do you see the problem and to exactly (£££) what degree?

small crow
15/1/2019
06:45
Can't quite see it so equivocally - but that article is more reassuring than what I could find...the wrinkle of fee waiver adds a question in my mind. Timing seems to be a little tight before the money runs out...on balance though fair to think it shouldn't be impacted...
123js
14/1/2019
22:34
Well at least one bluey on this thread is clearly hoping to get in lower! Expect a bit of deramping tomorrow.
bountyhunter
14/1/2019
20:59
Topped up today. If approved as a new antibiotic Iclaprim will be of huge significant globally especially with resistance to existence antibiotics increasing all the time.
bountyhunter
14/1/2019
20:56
hxxps://www.stitcher.com/podcast/justin-waite/happy-hour-from-happymapcom/e/56631689

Good listen 10.45 in

ianb5004
14/1/2019
20:55
hxxps://www.statnews.com/2019/01/14/shutdown-impact-on-drug-approvals/

As you can see this will NOT effect the Approval decision for Iclaprim only new NDA submissions.

ianb5004
14/1/2019
17:02
The relevant piece in the article seems to be:-

"While the FDA is continuing to carry out reviews funded by fiscal year (FY) 2018 Prescription Drug User Fee Act user fees, including the review and approval of new drugs and biologics funded by carryover user fee balances, the agency is not accepting FY 2019 user fees until funding appropriations have been authorized, i.e., the political impasse has been resolved. Consequently, the FDA has suspended reviews of existing Investigational New Drug (IND) and Biologics License Application (BLA) applications not covered by user fees, and is not reviewing applications for new drugs and biologics submitted during the shutdown period, except for emergency INDs and BLAs."

As Motif Bio's review began in August 2018, surely that shouldn't be affected?

alan@bj
14/1/2019
13:45
Could be.www.forbes.com/sites/joshuacohen/2019/01/10/partial-government-shutdowns-impact-on-fda-drug-approvals/#229980fb2d08
richard xii
14/1/2019
13:24
Does government shutdown impact timing here? Activities funded by fees continue - ie new drug review and approvals - but if that fee is waived does that complicate?
123js
11/1/2019
16:42
Nice run of trades in the last hour and rise into the close bodes well for Monday
return_of_the_apeman
11/1/2019
14:43
Thanks return_of_the_apeman. We will have an interesting 2019 if the FDA gives its approval.
richard xii
Chat Pages: Latest  109  108  107  106  105  104  103  102  101  100  99  98  Older

Your Recent History

Delayed Upgrade Clock